Janet B. McGill

Janet B. McGill

Auto-generated profile, based on publicly available information

Janet B. McGill

Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis, School of Medicine St. Louis Missouri USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JMJanet B. McGill
Janet B. McGill
SSSavitha Subramanian
Savitha Subramanian

5 October 2023 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
HHHiddo Heerspink
Hiddo Heerspink
ABAndreas L. Birkenfeld
Andreas L. Birkenfeld
DCDavid Z.I. Cherney
David Z.I. Cherney
HCHelen M. Colhoun
Helen M. Colhoun
LJLinong Ji
Linong Ji
JMJanet B. McGill
Janet B. McGill
Despite guideline-recommended treatments, including RAS inhibition, up to 40% of individuals with T1D develop chronic kidney disease (CKD) putting them at risk of kidney failure. Finerenone is approved to reduce the risk of kidney failure in individuals with T2D. We postulate that finerenone will demonstrate benefits on kidney outcomes in people with T1D. FINE-ONE (NCT05901831) is a randomised, placebo-controlled, double-blind phase III trial of 7.5 months' duration in ∼220 adults with T1D, UACR of ≥200-<5000 mg/g (≥22.6-<565 mg/mmol) and eGFR of ≥25-‍<90 ml/min/1.73 m2. The primary endpoint is relative change in UACR from baseline over 6 months. UACR is used as a bridging biomarker (BB), since the treatment effect of finerenone on UACR was associated with its efficacy on kidney outcomes in the T2D trials. Based on regulatory authority feedback, UACR can be used as a BB for kidney outcomes to support registration of finerenone in T1D, provided necessary criteria are met. Secondary outcomes include incidences of treatment-emergent adverse events, treatment-emergent serious adverse events and hyperkalaemia. FINE-ONE will evaluate the efficacy and safety of finerenone in T1D and CKD. Finerenone could become the first registered treatment for CKD associated with T1D in almost 30 years. ClinicalTrials.gov NCT05901831.

31 October 2022 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
GFGregory Forlenza
Gregory Forlenza
ACAnders L. Carlson
Anders L. Carlson
RGRodolfo J. Galindo
Rodolfo J. Galindo
DKDavida F. Kruger
Davida F. Kruger
CLCarol J. Levy
Carol J. Levy
GAGrazia Aleppo
Grazia Aleppo
Background: The Tandem Control-IQ (CIQ) system has demonstrated significant glycemic improvements in large randomized controlled and real-world trials. Use of this system is lower in people with type 1 diabetes (T1D) government-sponsored insurance and those with type 2 diabetes (T2D). This analysis aimed to evaluate the performance of CIQ in these groups. Methods and Materials: A retrospective analysis of CIQ users was performed. Users age ≥6 years with a t:slim X2 Pump and >30 days of continuous glucose monitoring (CGM) data pre-CIQ and >30 days post-CIQ technology initiation were included. Results: A total of 4243 Medicare and 1332 Medicaid CIQ users were analyzed among whom 5075 had T1D and 500 had T2D. After starting CIQ, the Medicare beneficiaries group saw significant improvement in time in target range 70–180 mg/dL (TIR; 64% vs. 74%; P < 0.0001), glucose management index (GMI; 7.3% vs. 7.0%; P < 0.0001), and the percentage of users meeting American Diabetes Association (ADA) CGM Glucometrics Guidelines (12.8% vs. 26.3%; P < 0.0001). The Medicaid group also saw significant improvement in TIR (46% vs. 60%; P < 0.0001), GMI (7.9% vs. 7.5%; P < 0.0001), and percentage meeting ADA guidelines (5.7% vs. 13.4%; P < 0.0001). Patients with T2D and either insurance saw significant glycemic improvements. Conclusions: The CIQ system was effective in the Medicare and Medicaid groups in improving glycemic control. The T2D subgroup also demonstrated improved glycemic control with CIQ use. Glucometrics achieved in this analysis are comparable with those seen in previous randomized controlled clinical trials with the CIQ system.

1 January 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
SGSatish K. Garg
Satish K. Garg
GGGeorge Grunberger
George Grunberger
RWRuth S Weinstock
Ruth S Weinstock
MLMargaret L. Lawson
Margaret L. Lawson
IHIrl B. Hirsch
Irl B. Hirsch
MCMary Jane Clifton
Mary Jane Clifton
Objective: To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 months in persons with type 1 diabetes (T1D). Methods: Adults (aged 18–80 years), adolescents, and children (aged 2–17 years) with T1D who were using CSII therapy were enrolled and randomized (1:1) to 6 months of HCL intervention (n = 151, mean age of 39.9 ± 19.8 years) or CSII without continuous glucose monitoring (n = 151, 35.7 ± 18.4 years). Primary effectiveness endpoints included change in A1C for Group 1 (baseline A1C >8.0%), from baseline to the end of study, and difference in the end of study percentage of time spent below 70 mg/dL (%TBR <70 mg/dL) for Group 2 (baseline A1C ≤8.0%), to show superiority of HCL intervention versus control. Secondary effectiveness endpoints were change in A1C and %TBR <70 mg/dL for Group 2 and Group 1, respectively, to show noninferiority of HCL intervention versus control. Primary safety endpoints were rates of severe hypoglycemia and diabetic ketoacidosis (DKA). Results: Change in A1C and difference in %TBR <70 mg/dL for the overall group were significantly improved, in favor of HCL intervention. In addition, a significant mean (95% confidence interval) change in A1C was observed for both Group 1 (−0.8% [−1.1% to −0.4%], P < 0.0001) and Group 2 (−0.3% [−0.5% to −0.1%], P < 0.0001), in favor of HCL intervention. The same was observed for difference in %TBR <70 mg/dL for Group 1 (−2.2% [−3.6% to −0.9%]) and Group 2 (−4.9% [−6.3% to −3.6%]) (P < 0.0001 for both). There was one DKA event during run-in and six severe hypoglycemic events: two during run-in and four during study (HCL: n = 0 and CSII: n = 4 [6.08 per 100 patient-years]). Conclusions: This RCT demonstrates that the MiniMed 670G HCL safely and significantly improved A1C and %TBR <70 mg/dL compared with CSII control in persons with T1D, irrespective of baseline A1C level.

5 July 2022 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
JMJanet B McGill
Janet B McGill
HHHermann Haller
Hermann Haller
PRPrabir Roy-Chaudhury
Prabir Roy-Chaudhury
ACAndrea Cherrington
Andrea Cherrington
TWTakashi Wada
Takashi Wada
PRPeter Rossing
Peter Rossing
Albuminuria is useful for early screening and diagnosis of kidney impairment, especially in people with pre-diabetes or type 2 diabetes (T2D), which is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD), associated with increased mortality, poor cardiovascular outcomes, and high economic burden. Identifying patients with CKD who are most likely to progress to ESKD permits timely implementation of appropriate interventions. The early stages of CKD are asymptomatic, which means identification of CKD relies on routine assessment of kidney damage and function. Both albuminuria and estimated glomerular filtration rate are measures of kidney function. This review discusses albuminuria as a marker of kidney damage and cardiorenal risk, highlights the importance of early screening and routine testing for albuminuria in people with T2D, and provides new insights on the optimum management of CKD in T2D using albuminuria as a target in a proposed algorithm. Elevated urine albumin can be used to detect CKD in people with T2D and monitor its progression; however, obstacles preventing early detection exist, including lack of awareness of CKD in the general population, poor adherence to clinical guidelines, and country-level variations in screening and treatment incentives. With albuminuria being used as an entry criterion and a surrogate endpoint for kidney failure in clinical trials, and with novel treatment interventions available to prevent CKD progression, there is an urgent need for early screening and diagnosis of kidney function decline in people with T2D or pre-diabetes.

25 October 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
JHJing W. Hughes
Jing W. Hughes
YBYicheng K. Bao
Yicheng K. Bao
MSMaamoun Salam
Maamoun Salam
PJPrajesh Joshi
Prajesh Joshi
CKC. Rachel Kilpatrick
C. Rachel Kilpatrick
JMJanet B. McGill
Janet B. McGill
OBJECTIVE: Type 1 diabetes (T1DM) is associated with other autoimmune diseases (AIDs), which may have serious health consequences. The epidemiology of AIDs in T1DM is not well defined in adults with T1DM. In this cross-sectional cohort study, we sought to characterize the incident ages and prevalence of AIDs in adults with T1DM across a wide age spectrum. RESEARCH DESIGN AND METHODS: A total of 1,212 adults seen at the Washington University Diabetes Center from 2011 to 2018 provided informed consent for the collection of their age, sex, race, and disease onset data. We performed paired association analyses based on age at onset of T1DM. Multivariate logistic regression was used to evaluate the independent effects of sex, race, T1DM age of onset, and T1DM duration on the prevalence of an additional AID. RESULTS: Mean ± SD age of T1DM onset was 21.2 ± 14.4 years. AID incidence and prevalence increased with age. Female sex strongly predicted AID risk. The most prevalent T1DM-associated AIDs were thyroid disease, collagen vascular diseases, and pernicious anemia. T1DM age of onset and T1DM duration predicted AID risk. Patients with late-onset T1DM after 30 years of age had higher risks of developing additional AIDs compared with patients with younger T1DM onset. CONCLUSIONS: The prevalence of AIDs in patients with T1DM increases with age and female sex. Later onset of T1DM is an independent and significant risk factor for developing additional AIDs. Individuals who are diagnosed with T1DM at older ages, particularly women, should be monitored for other autoimmune conditions.